Table 1.
Selected novel therapies for mRCC discussed in the current manuscript.
| Therapeutic Class | Agent | Description |
|---|---|---|
| Angiogenesis Inhibitors | AMG-386 | Peptibody disrupting interaction between Ang-1/2 and Tie-2. |
| CVX-060 | Fusion protein comprised of two Ang-2 binding peptides | |
| CVX-241 | Fusion protein with affinity for both VEGF and Ang-2 | |
| Thalidomide | Immunomodulator; precise mechanism unknown | |
| Lenalidomide | Immunomodulator; precise mechanism unknown | |
| Immunotherapy | BMS-936558 (MDX-1106) | Fully human IgG4 blocking PD-1 |
| IMA901 | Vaccine derived from TAAs, including 9 HLA-class I and 1 HLA- class II binding peptides | |
| AGS-003 | Autologous dendritic cell vaccine generated through electroporation of tumor-derived RNA and CD40L | |
| MGN-1601 | Allogeneic vaccine comprised of human RCC cells modified to express IL-7, GM-CSF, CD80, and CD154 | |
| Ipilimumab | Monoclonal antibody with affinity for CTLA4 | |
| Cytotoxic Therapy | S-1 | Oral formulation comprised of tegafur, potassium oxonate, and 5- choloro-2,4-dihydroxypyridine |
| Ixabepilone | Novel epothilone inhibiting microtubule function | |
| Targeted Agents | XL184 | Small molecule inhibitor of VEGFR2 and MET |
| ARQ197 | Small molecule inhibitor of MET | |
| AMG-102 | Monoclonal antibody with affinity for HGF | |
| Dovitinib (TKI-258) | Small molecule inhibitor of FGFR1-3 | |
| Brivanib | Small molecule inhibitor of VEGFR and FGFR1-3 |